Alolaby Reem Rafik, Jiraanont Poonnada, Durbin-Johnson Blythe, Jasoliya Mittal, Tang Hiu-Tung, Hagerman Randi, Tassone Flora
College of Health Sciences, California Northstate University, Rancho Cordova, CA, United States.
Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Bangkok, Thailand.
Front Genet. 2020 Apr 15;11:308. doi: 10.3389/fgene.2020.00308. eCollection 2020.
Sertraline is one among several selective serotonin reuptake inhibitors (SSRIs) that exhibited improvement of language development in Autism Spectrum Disorder (ASD); however, the molecular mechanism has not been elucidated. A double blind, randomized, 6-month, placebo-controlled, clinical trial of low-dose sertraline in children ages (3-6 years) with ASD was conducted at the UC Davis MIND Institute. It aimed at evaluating the efficacy and benefit with respect to early expressive language development and global clinical improvement. This study aimed to identify molecular biomarkers that might be key players in the serotonin pathway and might be predictive of a clinical response to sertraline. Fifty eight subjects with the diagnosis of ASD were randomized to sertraline or placebo. Eight subjects from the sertraline arm and five from the placebo arm discontinued from the study. Furthermore, four subjects did not have a successful blood draw. Hence, genotypes for 41 subjects (20 on placebo and 21 on sertraline) were determined for several genes involved in the serotonin pathway including the serotonin transporter-linked polymorphic region (), the tryptophan hydroxylase 2 (), and the Brain-Derived Neurotrophic Factor (). In addition, plasma levels of , Matrix metallopeptidase 9 () and a selected panel of cytokines were determined at baseline and post-treatment. Intent-to-treat analysis revealed several primary significant correlations between molecular changes and the Mullen Scales of Early Learning (MSEL) and Clinical Global Impression Scale - Improvement (CGI-I) of treatment and control groups but they were not significant after adjustment for multiple testing. Thus, sertraline showed no benefit for treatment of young children with ASD in language development or changes in molecular markers in this study. These results indicate that sertraline may not be beneficial for the treatment of children with ASD; however, further investigation of larger groups as well as longer term follow-up studies are warranted.
舍曲林是几种选择性5-羟色胺再摄取抑制剂(SSRI)之一,这些抑制剂在自闭症谱系障碍(ASD)中显示出语言发育的改善;然而,其分子机制尚未阐明。加利福尼亚大学戴维斯分校心智研究所对年龄在3至6岁的ASD儿童进行了一项双盲、随机、为期6个月、安慰剂对照的低剂量舍曲林临床试验。该试验旨在评估早期表达性语言发育和整体临床改善方面的疗效和益处。本研究旨在确定可能是5-羟色胺途径中的关键参与者且可能预测对舍曲林临床反应的分子生物标志物。58名被诊断为ASD的受试者被随机分为舍曲林组或安慰剂组。舍曲林组有8名受试者、安慰剂组有5名受试者退出了研究。此外,有4名受试者未能成功采血。因此,对41名受试者(20名服用安慰剂,21名服用舍曲林)的几种参与5-羟色胺途径的基因进行了基因分型,这些基因包括5-羟色胺转运体相关多态性区域()、色氨酸羟化酶2()和脑源性神经营养因子()。此外,在基线和治疗后测定了血浆中、基质金属蛋白酶9()和一组选定细胞因子的水平。意向性分析揭示了分子变化与治疗组和对照组的早期学习穆伦量表(MSEL)及临床总体印象量表-改善(CGI-I)之间的几个主要显著相关性,但在进行多重检验校正后这些相关性并不显著。因此,在本研究中舍曲林对ASD幼儿的语言发育或分子标志物变化没有治疗益处。这些结果表明舍曲林可能对ASD儿童的治疗无益;然而,有必要对更大的群体进行进一步研究以及开展长期随访研究。